Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment

Cervical cancer, breast cancer, and ovarian cancer are the most prevalent cancers seen at Dr. Moewardi Surakarta Hospital, and carboplatin-paclitaxel chemotherapy is prescribed in 45% of incidents. Alopecia was identical to chemotherapy.

Methods

The study aims to identify the type, percentage, and severity of Adverse Drug Reactions to alopecia in RSUD Dr. Moewardi Surakarta. This was an observational research using a cross-sectional design with prospective data searches. This study's inclusion criteria were adults with cancer who received carboplatin-paclitaxel treatment and were willing to participate in the research. The data on ADRs and the severity of alopecia will be described as a percentage.

Result

Alopecia was the most common ADR in participants taking carboplatin-paclitaxel in this research. 100% of patients had alopecia due to the carboplatin-paclitaxel regimen. The current study measured the severity by CTCAE with ADR values at grades 2 (100%).